CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
BioArctic Neuroscience is developing a biomarker assay for Parkinson’s disease that aims to provide an early and accurate diagnosis. This assay measures specific forms of alpha-synuclein in cerebrospinal fluid, addressing the critical need for reliable diagnostic tools in neurodegenerative disorders.
Parkinson’s disease (PD) is one of the most prevalent neurodegenerative disorders and a disease with a significant unmet medical need.
World-wide, more than 4.6 million individuals over the age of 50 suffer from PD and it is estimated that the number will more than double by 2030.
The economic impact of the disease is enormous and the estimated annual European cost of PD is 14 billion euros.
At present, only symptomatic therapies are available for PD and there is a huge unmet need for treatments…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
